AnHeart Therapeutics
Department of Oncology, Shanghai Pulmonary Hospital, Affiliated to Tongji University School of Medicine, Shanghai, China.
Prof. Dr. Caicun Zhou, Ph.D., MD, is the director of the Department of Oncology, at Shanghai Pulmonary Hospital, director of the Cancer Institute of Tongji University Medical School, and chairman of the Oncology Department of Tongji University. He studied in Japan for two years and was a visiting scientist in the USA for half a year. Professor Zhou is a committee member of the Chinese Association of Lung Cancer and the Chinese Society of Clinical Oncology and is a council member of the Shanghai Anti-cancer Association, the Shanghai Pneumonology Association, and the Shanghai Oncology Association. He serves as a member on the editorial boards of many scientific journals, including ‘Tumor’, ‘The Chinese-German Journal of Clinical Oncology, ‘China Oncology’ and the ‘Chinese Journal of Clinical Oncology and also an associate editor of Lung Cancer. Professor Zhou was selected as an ‘Excellent learning pioneer’ by the Science and Technology Commission of Shanghai Municipality (STCSM) in 2006 and got grants from the National 863 project and five other key research projects of the STCSM. His major research interests are in customized and targeted therapy for lung cancer, and he has published over 100 papers in scientific journals.
This person is not in the org chart
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.